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Abstract 
 
Aims. The non-vitamin K antagonist oral anticoagulants (NOACs) have varying degrees of renal 
elimination which may be challenging in patients with heart failure (HF) and atrial fibrillation (AF). 
We examined the severity and variation in renal impairment, and the proportion of patients 
requiring NOAC cessation or dose reduction. 
 
Methods and results. Retrospective analysis of patients with HF and AF in the Candesartan in 
Heart failure Assessment of Reduction in Mortality and Morbidity program. Trends in renal 
impairment over 26 months were defined using Cockcroft-Gault (CG), simplified Modification of 
Diet in Renal Disease (MDRD), and Chronic Kidney Disease Epidemiology Collaborative (CKD-
EPI) equations. Mean eGFR was worse at every time point in patients with AF compared to those 
without AF, the difference being approximately 11 ml/min (CG), 9 ml/min (CKD-EPI) and 7 
ml/min (MDRD). As renal function declined, CG classified a greater proportion of patients as 
having moderate or severe CKD and agreement with MDRD/CKD-EPI declined. At least moderate 
renal impairment was present in one quarter of patients with AF at baseline, one third by study 
completion, and approaching one half at least once during follow-up. The projected need for NOAC 
dose reduction was accordingly high, though varied between individual NOACs due to different 
criteria for adjustment. 
 
Conclusions. Renal impairment in patients with HF and AF is common, fluctuates, progresses, and 
frequently mandates NOAC dose reduction, though the need for cessation is rare.  Baseline renal 
function, the method of estimating GFR, and intensity of monitoring should be considered when 
commencing oral anticoagulation. 
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Abbreviations 
ACEI – angiotensin enzyme converting inhibitor 
AF – atrial fibrillation 
AF-CHF – Atrial Fibrillation and Congestive Heart Failure  
ARISTOTLE – Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 
Fibrillation 
BSA – body surface area 
CG – Cockcroft-Gault 
CKD – chronic kidney disease 
CKD-EPI – Chronic Kidney Disease Epidemiology Collaborative 
eGFR – estimated glomerular filtration rate 
EMA – European Medicines Agency 
ENGAGE AF – Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation 
LVEF – left ventricular ejection fraction 
HF – heart failure 
NYHA – New York Heart Association 
MDRD – Modification of Diet in Renal Disease 
NOACs – non-vitamin K antagonist oral anticoagulant drugs 
RELY – Randomized Evaluation of Long-Term Anticoagulation Therapy 
ROCKET-AF - Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin 
K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation
 4 
 
Introduction 
 
Heart failure (HF), atrial fibrillation (AF) and chronic kidney disease (CKD) form a complex and 
dangerous triad.  Their incidence, prevalence and severity are all interrelated, through shared 
pathophysiological mechanisms and risk factors such as diabetes and hypertension.  Each is a 
powerful independent and additive predictor of mortality and hospitalisations.1, 2  The confluence of 
all three also engenders a thrombotic-haemorrhagic paradox: CKD and HF increase both the risk of 
stroke and the risk of haemorrhage in patients with AF.3-6  The balance between the benefit and risk 
of anticoagulation in AF patients with significant CKD is uncertain, which is a particular concern in 
HF where the combination of CKD and AF is especially common.  In the EuroHeart Surveys for HF 
and AF, a history of renal insufficiency was present in 13% and 10% of patients with concurrent AF 
and HF respectively.7, 8 This prevalence doubled to 20% in patients hospitalized with HF in the Get 
With The Guidelines registry.9 However, over half of patients admitted to a Spanish hospital with 
decompensated HF had significant renal impairment when defined using eGFR < 60 ml/min.10 
Although the pivotal trials of non-vitamin K antagonist oral anticoagulant drugs (NOACs) 
included patients with HF (approximately one third of patients in ARISTOTLE and RELY, over 
one half in ENGAGE AF, and two thirds in ROCKET-AF),11-14  individuals with severe CKD 
(creatinine clearance < 25 or 30 ml/min) were excluded as NOACs exhibit varying degrees of renal 
excretion. In patients with lesser degrees of renal dysfunction NOAC dose adjustment is 
recommended.15  Use of NOACs in patients with HF may therefore be complicated by concomitant 
CKD, not just at the time of initiation but also subsequently given that renal dysfunction tends to 
decline over time in HF.  To better understand this potential problem, we examined the proportion 
of patients with moderate or severe renal impairment that would prompt NOAC dose adjustment at 
baseline and adjustment or discontinuation over follow up in the Candesartan in Heart failure 
Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
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Methods 
 
The rationale, methods, eligibility criteria and outcomes of the CHARM programme have 
been published previously.16, 17  Key exclusion criteria included serum creatinine e  3 mg/dL (265 
¼mol/L), serum potassium e  5.5 mmol/L, known bilateral renal artery stenosis, symptomatic 
hypotension, and critical valve disease.  Eligible consented patients with symptomatic heart failure 
(New York Heart Association [NYHA] class II-IV) were enrolled into one of three parallel clinical 
trials according to left ventricular ejection fraction (LVEF) and angiotensin converting enzyme 
inhibitor (ACEI) treatment: LVEF ≤ 40% and not receiving an ACEI due to previous intolerance 
(CHARM-Alternative, n=2028); LVEF ≤ 40% receiving ACEI treatment (CHARM-Added, 
n=2548); and LVEF > 40% (CHARM-Preserved, n=3023).  There were 7599 patients randomised, 
3803 receiving candesartan and 3796 placebo.  Patients enrolled in North America underwent 
central laboratory measurement of creatinine at baseline, 6 weeks, 14 months and 26 months (Visits 
1, 4, 7 and 10).  There were 2673 patients with a valid creatinine after exclusion of 2 patients with 
baseline serum creatinine concentration recorded > 10 mg/dL. 
 
Population with atrial fibrillation 
 
The CHARM dataset contains 3 variables referring to AF: medical history of AF (n=2084), 
AF on baseline ECG (n=1148);18 and new AF detected during the study (n=392).19 Overall 2527 
(33.3%) of patients had AF defined by one or more of these variables.  Previous CHARM analyses 
have examined patients with baseline ECG AF,18 or development of new AF.19  However, this does 
not capture a proportion of patients for whom anticoagulation is indicated with either paroxysmal 
AF or persistent AF restored to sinus rhythm before enrolment.  Conversely, including all patients 
with a history of reported AF likely overestimates the population requiring anticoagulation, as 
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diagnoses may be inaccurate or include isolated episodes (e.g. sepsis, peri-operative) for which 
lifelong anticoagulation is inappropriate.  We compromised by including patients with a history of 
AF who were also prescribed anticoagulants at baseline.  The final group with AF consisted of 1666 
(21.9%) patients: baseline ECG AF (n=1148) and prior AF with baseline anticoagulation (n=1348 
of whom 830 with baseline ECG AF). 
 
eGFR equations 
 
Estimated GFR (ml/min) was calculated using three widely accepted methods,20, 21 the 
Cockcroft-Gault (CG),22 simplified Modification of Diet in Renal Disease (MDRD),23 and Chronic 
Kidney Disease Epidemiology Collaborative (CKD-EPI) equations.  Pharmacokinetic studies and 
NOAC clinical trials have used the CG method to estimate renal function, leading to adoption as the 
standard for drug dosing and drug labels.  The equation includes weight and estimates raw 
creatinine clearance without normalisation to body surface area (BSA), thus being particularly 
relevant to drug elimination.  The CG formula is recommended for drug dosing by the National 
Kidney Foundation and the product monograph of all four NOACs.  Actual as opposed to ideal 
body weight was utilised as estimates based on actual weight demonstrate greater concordance with 
measured GFR.24 CG eGFR (= [140 – age] × weight (kg) × 1.23 or 1.03 (males or females) / serum 
creatinine (µmol/L). 
By contrast, both the MDRD and CKD-EPI equations estimate GFR adjusted for BSA 
(ml/min/1.73m2) using serum creatinine, age, sex and race.  We de-normalised results to estimate 
raw GFR by multiplying by BSA divided by 1.73 m2.24, 25  BSA was calculated with the Dubois and 
Dubois formula as used to develop the MDRD and CKD EPI formula,23 where BSA(m2) = 
0.007184 × height0.725 (cm) × weight0.425 (kg).26  The original simplified MDRD four component 
equation,21, 23, 27, 28 was subsequently re-expressed for serum creatinine standardised to isotope 
dilution mass spectrometry (IDMS),29, 30 permitting direct comparison with the IDMS calibrated 
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CKD-EPI definitions. MDRD eGFR = 30849 × (Scr µmol/L)-1.154 × (age)-0.203 × 0.742 [if female] × 
1.212 [if black]. 
The CKD-EPI formula was derived from a larger, more representative sample of the U.S. 
population.31  The principal benefit is improved accuracy compared with the MDRD formula for 
estimates higher than 60 ml/min/1.73m2.  The CKD-EPI single equation is eGFR = 141 × 
min(Scr/º , 1)± × max(Scr/º , 1)-1.209 × (0.993)Age × 1.018 [female] × 1.159 [if black], where Scr is 
serum creatinine, º  is 0.7 for females and 0.9 for males, ± is -0.329 for females and -0.411 for 
males, min indicates the minimum of Scr/º  or 1, and max indicates the maximum of Scr/º  or 1.31 
 
Statistical analysis and renal impairment classification 
 
Unadjusted (ml/min) and body surface area adjusted (ml/min/1.73m2) estimates of GFR are 
respectively employed to describe renal impairment for drug dosing and the extent of renal disease.  
Severity of both entities is classified using identical thresholds.  A renal clearance drug is removed 
from the body proportional to absolute (unadjusted) creatinine clearance rather than the normalised 
version.  A normalised GFR will under- and over-estimate drug removal in large and small patients 
respectively.  We therefore present unadjusted or denormalised values. 
Severity of renal impairment was graded according to eGFR (ml/min) and the European 
Medicines Agency (EMA) as recommended in all four NOAC product monographs (Table 1): 
normal (>80), mild (50 – 80), moderate (30 – 50), severe (15 – 30), very severe (<15).  These differ 
from the National Kidney Foundation thresholds for normal and mild renal impairment (90 and 60 
respectively).32  Data are reported as frequencies and percentages.  Logistic regression was used to 
identify independent predictors of moderate and severe renal impairment according to CG equation.  
The following 15 baseline variables were selected as candidate predictors of worsening renal 
function (WRF) based on univariate association (p<0.1) (eGFR, candesartan treatment, systolic 
blood pressure, diuretics, age, height, weight, urea, haemoglobin) or clinical rationale combined 
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with results of recent meta-analysis of WRF in HF (ACEI, sex, ejection fraction, diabetes, 
hypertension, spironolactone).33 
 
Impact of candesartan treatment 
In CHARM overall, candesartan titration was associated with a significant decrease in eGFR 
at 6 weeks relative to placebo (-5.0 ± 18.4 versus -0.4 ± 17.9 mL/min (p<0.001)), with no further 
significant treatment-time interaction beyond the titration phase. We included the 6 week time point 
in the primary analysis to reflect clinical practice in which neurohormonal antagonists and diuretics 
are regularly introduced and titrated, and because candesartan treatment was only one among a 
number of predictors of worsening renal function. Moreover, the associated decline in eGFR had 
minimal impact on the total proportion of patients with moderate or severe renal impairment during 
long term follow-up. A sensitivity analysis excluding measurements at the 6 week time point is 
presented in the online Appendix). 
 
Results 
 
Baseline characteristics stratified by presence of AF and severity of renal impairment are 
presented in Online Appendix Tables 1 and 2. Compared to patients without AF, those with AF 
were older, had a more frequent history of hypertension and stroke, higher virtual CHADS2 scores 
(mean 2.8 (SD 1.1) vs. 2.5 (SD 1.0), p<0.001), and were more often prescribed oral anticoagulation, 
digoxin and amiodarone. 
Mean eGFR was worse at every time point in patients with AF compared to those without 
AF, irrespective of the estimation method (p<0.001 for every comparison).  The difference in means 
was approximately 11 ml/min (CG), 9 ml/min (CKD-EPI) and 7 ml/min (MDRD) (Table 2). At 
baseline, one quarter of patients with AF had at least moderate renal impairment (eGFR <50 
ml/min) estimated using CG (27.9%), MDRD (26.5%), or CKD-EPI (26.7%) (Table 2).  The 
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prevalence of at least moderate renal impairment in patients with AF increased over time, whether 
measured using either CG, MDRD or CKD-EPI: CG at baseline, 6 weeks, 14 months and 26 
months respectively 27.9%, 31.5%, 35.3% and 34.0% (p=0.07); MDRD 26.5%, 29.9%, 33.2%, 
29.7% (p=0.16); CKD-EPI 26.7%, 29.5%, 32.7%, 29.4% (p=0.24). 
 
Fluctuation of CKD severity over time 
 
Among the 2673 patients with documented baseline creatinine, 2530 had at least one 
additional measurement. CKD severity according to CG, MDRD and CKD-EPI remained stable or 
improved in around two thirds (67.7%, 64.1% and 67.7% respectively) of patients with AF and 
serial measurements, and declined in the remaining third (32.3%, 35.9% and 32.3% respectively) 
(Table 3). Considering only moderate or severe CKD, one fifth of patients with AF were stable 
from baseline onwards (CG 22.6%, MDRD 20.3%, CKD-EPI 20.7%).  A similar proportion had 
worsening renal impairment of at least moderate severity across the four visits (CG 21.4%, MDRD 
23.7%, CKD-EPI 22.4%).  Considering all time points, nearly half (44.0%) of patients with AF had 
either stable or fluctuating moderate or severe renal impairment applying the Cockcroft-Gault 
formula and EMA classification as recommended in the product monograph.  This was greater than 
observed in patients without AF (44.0% vs 30.4%, p<0.001). Sensitivity analysis excluding 
creatinine measurements at week 6 (the candesartan titration phase) yielded similar results (42.0% 
vs 28.5%, p<0.001) (Online Appendix Table 3). 
 
Prediction of moderate or severe CKD by baseline eGFR 
 
Deterioration by greater than one severity class was unusual.  Most patients who developed 
moderate renal impairment (<50 ml/min) during the study had mild baseline dysfunction (<80 
ml/min).  Likewise, most patients who developed severe renal impairment (<30 ml/min) had 
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moderate baseline dysfunction (<50 ml/min) (Figure 1).  Four independent predictors of worsening 
moderate to severe renal impairment were identified (Table 4).  Baseline eGFR (OR 1.20 [1.10 – 
1.30] per 10 ml/min decrease) and allocation to candesartan treatment (OR 2.54 [1.60 – 4.05]) were 
the most powerful predictors, with background ACE inhibitor treatment, diuretics and systolic 
blood pressure exhibiting modest predictive value. 
 
Concordance between EMA classes applying Cockcroft-Gault, MDRD and CKD-EPI formula 
 
Among patients with AF, the concordance between EMA class according to CG and MDRD 
was high in the normal eGFR range (80% concordance > 80 ml/min) but declined with declining 
renal function (66% concordance <30 ml/min) (Figure 2A).  A similar pattern was observed 
comparing CG against CKD-EPI (Figure 2B).  With worsening renal function MDRD or CKD-EPI 
typically classified kidney dysfunction as less severe than did the CG equation.  For example, at 
baseline 25% and 23% of patients with AF classified as moderate CKD by CG were reclassified as 
mild CKD by the MDRD and CKD-EPI estimates, respectively.  However, only a minority of 
patients (10%) classified as having moderate CKD by the MDRD and CKD-EPI equations had a 
milder degree of renal function according to the CG estimate.  These relationships held true for 
patients with and without AF (data not presented).  Concordance of EMA classes based on MDRD 
compared with CKD-EPI was very high for all levels of severity (93% to 99%) (Figure 2C). 
 
Incidence of recommended dose reduction or discontinuation due to renal impairment 
 
In the US, all four licensed NOACs are contraindicated in very severe renal impairment 
(eGFR <15 ml/min) which was rare during follow-up (0.4%).  However, edoxaban is also not 
recommended in patients with eGFR >95 ml/min, which precluded over one quarter of patients 
(23.6% at baseline and a further 5.7% during follow-up). 
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Apixaban dose reduction (2 of 3 criteria Table 1) was projected in 7.0% and 3.4% of 
patients at baseline and follow-up, respectively (Figure 3, and Online Appendix Table 4).  In the 
US, dabigatran dose reduction is only indicated in severe renal impairment (eGFR 15 – 30 ml/min), 
potentially affecting a similar proportion of patients to the apixaban criteria: 6.4% at baseline and 
5.4% during follow-up.  By contrast, rivaroxaban and edoxaban dose reduction is recommended in 
moderate or severe renal impairment (eGFR 15 – 50 ml/min), affecting 27.5% of patients at 
baseline and a further 15.7% during follow-up. 
European prescribing guidance is identical to the US for rivaroxaban, similar for apixaban, 
and more stringent for dabigatran and edoxaban (Table 1).  In Europe at baseline and follow-up 
respectively, renal impairment would prohibit dabigatran in 6.8% and 5.4% of patients, with dose 
reduction in 14.8% and 7.5% (Figure 3). Of the 6.8% ineligible for dabigatran at baseline, 2.0% 
experienced sufficient improvement in renal function to become eligible during follow-up. 
 
Discussion 
 
In this ambulatory clinical trial heart failure population, patients with concurrent AF had 
significantly greater renal impairment than those without AF, which fluctuated and progressed over 
time.  At least moderate renal impairment was present in one quarter of patients with AF at 
baseline, one third by study completion, and approaching one half at least once during follow-up.  
With worsening renal function CG classified a greater proportion of patients as having moderate or 
severe CKD and agreement with MDRD/CKD-EPI declined.  Although severe renal impairment 
was uncommon, a significant proportion of patients would require NOAC dose reduction at baseline 
or during follow-up. 
 
Severity and variability of renal impairment 
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Baseline renal dysfunction is common in both HF and AF cohorts and trial populations.33-35  
Worsening renal function is also common, observed in 23% of patients with HF in meta-analysis.33  
In the few studies examining WRF in AF, a similar proportion of patients experienced WRF to that 
seen in HF trials.34, 35  Both HF and AF have many reasons to either cause or be associated with 
baseline and worsening renal impairment, many of which may interact.  However, very few studies 
have defined renal function in patients with both conditions. In 1365 patients with systolic 
dysfunction and recent history of AF enrolled in the Atrial Fibrillation and Congestive Heart Failure 
(AF-CHF) trial,28 the severity of renal impairment was normal, mild, moderate and severe in 9%, 
44%, 43% and 3% of patients respectively.  Our baseline characteristics appear discordant with 
these findings (33%, 41%, 21%, 6%, respectively, based upon MDRD).  However, we de-
normalised estimates and employed EMA thresholds.  Re-analysis using normalised MDRD and 
National Kidney Foundation thresholds returns very similar results to the AF-CHF analysis (10%, 
39%, 44% and 7% respectively).  This highlights the impact of varying definitions when classifying 
severity. 
We extend the AF-CHF findings by comparing to HF ‘controls’ without AF, and examining 
renal function over time.  The severity and variability of renal impairment in those with HF and AF 
together exceeded that in HF alone. Mean eGFR was worse at every time point utilising any 
estimation method.  Accordingly, at least moderate renal impairment was around 50% more 
frequent in those with AF compared to those without (44.0% vs 30.4% over all periods using CG). 
A recent study found a similar proportion of renal impairment (57% with CrCl <60 mL/min) over 6 
months in patients discharged following decompensated HF with concurrent AF.10  
 
Anticoagulation dilemmas in patients with coexistent HF-AF-CKD 
 
Patients with HF-AF have high thromboembolic risk yet low levels of appropriate 
anticoagulation.  At best, two thirds of patients without contraindication receive oral 
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anticoagulation: 68% of concurrent HF in the Euro Heart Survey for AF;36 65% of concurrent AF in 
the Get With The Guidelines HF program.37  Moreover, HF is strongly associated with reduced time 
in therapeutic range (TTR), the single most important predictor of warfarin effectiveness and 
safety.38  To compound matters, renal impairment is also an independent predictor of low TTR, 
haemorrhagic complications, and warfarin underutilisation.4, 5, 37, 39 Moreover, an analysis from 
RELY recently demonstrated greater progression of renal impairment with warfarin compared to 
dabigatran, possibly due to VKA effects on vascular atherosclerosis and calcification.40  NOACs 
potentially address these issues through improved patient adherence and more consistent 
anticoagulation, yet at the same time renal impairment may increase bleeding risk and necessitate 
closer monitoring. 
 
Clinical relevance of renal impairment in NOAC therapy 
 
Maximum plasma concentrations and area under curve exposure increase with WRF, 
correlating with the extent of renal elimination for individual NOACs.  Anticoagulant effects 
increase accordingly, though are typically modest.  The clinical impact of pharmacodynamic 
changes is uncertain.  In the landmark AF trials, bleeding rates were higher in moderate renal 
insufficiency irrespective of treatment allocation.41-43  Overall efficacy and net clinical benefit 
compared to warfarin were consistent with the overall trials, with no significant heterogeneity 
across renal function strata. However, in RELY the relative reduction in major bleeding compared 
with warfarin was less in patients with eGFR <50 mL/min with either dabigatran dose.43 The 
opposite was true in ARISTOTLE, where the relative reduction for major bleeding associated with 
apixaban was greatest in patients with eGFR d50 ml/min.42 By contrast, no such interaction was 
observed between renal function, treatment and major bleeding in ROCKET-AF.41 Accordingly the 
updated European Heart Rhythm Association Practical Guide and a recent practical review both 
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suggest dabigatran be second choice in patients with moderate renal impairment, with preference 
expressed for apixaban, or reduced dose rivaroxaban or edoxaban.44, 45 
 
Clinical relevance of concordance between eGFR assessment methods 
 
Most biochemistry laboratories provide MDRD-derived eGFR normalised for BSA.  A 
recent cross-sectional community based study in elderly patients with AF found 15% of patients 
judged eligible for dabigatran applying MDRD were ineligible by CG equation.46  We also found 
relative to CG that MDRD reclassified one quarter of moderate CKD as mild.  Assuming CG 
measurements are relevant to the safety of dosing of NOACs (which is not certain), use of MDRD 
would result in a significant proportion of patients being over-treated or over-dosed. NOAC dose 
adjustment should be guided by CG estimates for many reasons: CG was employed in the pivotal 
NOAC trials, is recommended in the product monograph and international guidelines,44 estimates 
creatinine clearance without normalisation to BSA, and is accepted practice for pharmacokinetic 
studies and dose adjustment. 
 
Incidence of recommended dose reduction or discontinuation 
 
Very few patients developed renal impairment sufficient to mandate discontinuation of any 
NOAC according to EU guidance.  During follow-up the projected incidence of dose reduction was 
lowest for apixaban (7%) and highest for rivaroxaban and edoxaban (16%) due to the product 
labelling in relation to moderate renal impairment.  Surprisingly, an additional half of patients 
would require dose reduction of edoxaban at baseline, due to the combination of moderate renal 
impairment (CrCl 15–50 ml/min) and weight criteria (d60kg). 
The criteria for dabigatran diverge considerably between EU and US guidelines: the 
projected incidence of dose reduction or cessation was similar to apixaban using US guidance, but 
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approached that of rivaroxaban using the EU regulations.  The discrepancy is concerning given the 
high renal elimination of dabigatran and the recently reported effect of plasma concentrations on 
major bleeding.47 
 
Limitations 
 
This clinical trial population may underestimate the severity of renal impairment in real-life 
due to exclusion criteria, recruitment bias with younger patients and fewer comorbidities, and trial 
mandated close follow-up maintaining clinical stability; most pertinent of all, patients with a serum 
creatinine e  3 mg/dL (265 ¼mol/L) were excluded from CHARM. However, our findings reflect the 
minimum extent of the problem concerning NOAC use in patients with HF.  Temporal changes in 
some determinants of estimated renal function could not be assessed e.g. diuretic dose.  Severity is 
underestimated by survivorship i.e. patients with WRF which could precipitate excess 
anticoagulation and bleeding died prior to their next routine trial bloodwork.  Bleeding risk could 
not be assessed but may influence dose reduction decisions. The CHARM trial predates the NOAC 
era and may not accurately represent contemporary practice. In particular, mineralocorticoid 
receptor antagonists are now recommended for a broader spectrum of patients and may further 
impact renal function and NOAC eligibility. 
 
Conclusions 
 
Patients with HF and AF have greater renal impairment than those without AF.  Renal 
impairment fluctuates, progresses, and would frequently mandate NOAC dose reduction, though the 
need for cessation is rare.  Baseline renal function, the method of estimating GFR, and intensity of 
monitoring should be considered when commencing oral anticoagulation.  NOACs are the most 
commonly prescribed medication which require dose adjustment in renal impairment.  Just as 
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warfarin required organised systems of care, so too must health systems adapt to the new challenges 
of NOACs. 
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Table 1.  Summary of product monograph and renal information for the pivotal NOAC trials 
 
 Apixaban 
ARISTOTLE 
Dabigatran 
RELY 
Rivaroxaban 
ROCKET-AF 
Edoxaban 
ENGAGE AF 
Drug class Factor Xa inhibitor 
(FXa) 
Direct thrombin 
inhibitor (DTI) 
Factor Xa inhibitor 
(FXa) 
Factor Xa inhibitor 
(FXa) 
Renal excretion 25% renal 80% renal 30-40% renal 50% renal 
Landmark trial 
population 
stratified by eGFR 
25-30 n=268 
30-50 n=2737 
50-80 n=7587 
> 80 n=7518 
30 – 50 n=3374 
50 – 80 n=10697 
>80 n=3880 
30-50 n=1481 
50-80 n=3290 
> 80 n=2278 
30-50 n=4074 
 
Recommended 
method eGFR 
Cockcroft-Gault 
(ml/min) 
Cockcroft-Gault 
(ml/min) 
Cockcroft-Gault 
(ml/min) 
Cockcroft-Gault 
(ml/min) 
Recommended 
minimum renal 
monitoring 
Annually Annually if moderate 
renal impairment 
Annually - 
EU EMA revised 10/2015 revised 9/2015 revised 7/2015 revised 7/2015 
Dose reduction If 2 of 3: 
1) e  80 years 
2) d 60 kg 
3) sCr e  133µmol/L 
(1.5 mg/dL) 
or: 
CrCl 15 – 29 ml/min 
e  80 years 
e  75 years with 
additional bleeding 
risk factor including 
moderate impairment 
CrCl 30 – 50 ml/min 
CrCl 15 – 49 ml/min 
 
CrCl 15 – 50 ml/min 
or 
weight d60kg 
Contraindication CrCl < 15 ml/min CrCl < 30 ml/min CrCl < 15 ml/min CrCl < 15 ml/min 
US FDA revised 9/2015 revised 10/2015 revised 9/2015 revised 9/2015 
Dose reduction If 2 of 3: 
1) e  80 years 
2) d 60 kg 
3) sCr e  133µmol/L 
(1.5 mg/dL) 
CrCl 15 – 30 ml/min 
 
CrCl 15 – 50 ml/min 
 
CrCl 15 – 50 ml/min 
Contraindication CrCl < 15 ml/min CrCl < 15 ml/min CrCl < 15 ml/min CrCl < 15 ml/min 
CrCl > 95 ml/min 
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Table 2.  Severity of renal impairment in patients with and without atrial fibrillation, stratified by 
eGFR using the Cockcroft-Gault, de-normalised MDRD and CKD-EPI. 
 
 Cockcroft  MDRD  CKD-EPI  
AF No AF AF No AF AF No AF 
Baseline (n) 559 2114 559 2114 559 2114 
Mean (± SD) 74.4 (38.7) 86.4 (44.2) 70.5 (29.6) 78.6 (32.4) 71.0 (29.1) 80.2 (31.3) 
Normal (> 80) (%) 36.7 47.0 32.6 43.7 33.8 47.3 
Mild (50 – 80) (%) 35.4 34.1 41.0 38.2 39.5 35.0 
Moderate (30 – 49) (%) 21.1 15.3 20.8 15.0 20.2 14.5 
Severe (< 30) (%) 6.8 3.6 5.7 3.0 6.4 3.3 
At least moderate (%) 27.9 18.9 26.5 18.1 26.7 17.8 
6 weeks (n) 501 1902 501 1902 501 1902 
Mean (± SD) 73.4 (39.3) 84.4 (44.3) 68.6 (29.1) 76.5 (32.7) 69.4 (29.5) 78.1 (31.5) 
Normal (> 80) (%) 34.9 45.3 31.1 40.5 32.7 44.5 
Mild (50 – 80) (%) 33.5 34.3 38.9 38.3 37.7 34.8 
Moderate (30 – 49) (%) 24.0 16.4 23.2 17.0 22.4 16.6 
Severe (< 30) (%) 7.6 4.0  6.8 4.2 7.2 4.2 
At least moderate (%) 31.5 20.3 29.9 21.2 29.5 20.8 
14 months (n) 419 1657 419 1657 419 1657 
Mean (± SD) 70.6 (37.1) 82.1 (43.6) 66.0 (27.5) 74.0 (32.7) 67.2 (28.8) 75.8 (31.8) 
Normal (> 80) (%) 32.0 43.8 28.4 37.5 31.7 41.4 
Mild (50 – 80) (%) 32.7 33.9 38.4 39.2 35.6 35.9 
Moderate (30 – 49) (%) 27.2 17.0 25.5 17.7 25.1 16.8 
Severe (< 30) (%) 8.1 4.9 7.6 5.7 7.6 5.9 
At least moderate (%) 35.3 22.4 33.2 23.4 32.7 22.7 
26 months (n) 347 1386 347 1386 347 1386 
Mean (± SD) 73.6 (43.0) 83.8 (43.6) 68.3 (31.0) 75.2 (32.8) 69.2 (30.3) 77.3 (31.8) 
Normal (> 80) (%) 33.7 45.7 28.0 40.2 30.3 44.5 
Mild (50 – 80) (%) 32.3 32.6 42.4 37.2 40.3 33.7 
Moderate (30 – 49) (%) 28.5 17.1 23.6 17.5 23.1 16.4 
Severe (< 30) (%) 5.5 4.5 6.1 5.2 6.3 5.4 
At least moderate (%) 34.0 21.6 29.7 22.7 29.4 21.8 
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Table 3.  Proportion of patients with stable versus worsening renal impairment across serial 
measurements stratified by atrial fibrillation, according to the European Medicines Agency 
classification using the Cockcroft-Gault, MDRD and CKD-EPI methods. 
 
 CG  MDRD  CKD-EPI  
 AF No AF AF No AF AF No AF 
n with e  2 measures 527 2003 527 2003 527 2003 
Stable renal function (%) 67.7 71.2 64.1 63.9 67.7 65.9 
Normal (> 80) (%) 25.4 33.8 18.0 25.9 21.4 30.1 
Mild (50 – 80) (%) 19.7 23.5 25.8 25.3 25.6 23.1 
Moderate (30 – 49) (%) 16.7 10.9 15.6 10.0 15.2 9.7 
Severe (15 – 30) (%) 5.9 3.0 4.7 2.6 5.5 2.8 
Stable e  moderate (%) 22.6 13.9 20.3 12.6 20.7 12.6 
Worse renal function (%) 32.3 28.8 35.9 36.1 32.3 34.1 
Mild (>50) (%) 10.8 12.3 12.1 15.8 9.9 14.7 
Moderate (30 – 49) (%) 15.4 11.3 16.7 14.0 15.2 13.5 
Severe (15 – 30) (%) 5.7 4.7 6.5 5.8 6.6 5.5 
Very Severe (< 15) (%) 0.4 0.4 0.6 0.5 0.6 0.5 
Vary e  moderate (%) 21.4 16.5 23.7 20.3 22.4 19.5 
All e  moderate (%) 44.0 30.4 44.0 33.0 43.1 32.1 
 
 
 
 
Figure 1. Relative proportion of patients with AF stratified by baseline Cockcroft-Gault eGFR 
developing varying degrees of renal impairment during follow-up (moderate, severe or very severe). 
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Figure 2. Percentage of patients with AF reclassified into different EMA stages at baseline when 
estimating GFR using Cockcroft-Gault, MDRD and CKD-EPI equations. 
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Table 4. Independent predictors of worsening moderate to severe renal impairment. 
 
 Odds Ratio (95% CI) 
Multivariate Analysis 
Wald 
Chi 
p value 
eGFR (per 10 ml/min decrease) 1.20 (1.10 – 1.30) 14.7 <0.001 
Candesartan  2.54 (1.60 – 4.05) 15.4 <0.001 
Systolic BP (per 10 mmHg increase) 1.16 (1.04 – 1.29) 6.5 0.011 
ACE inhibitor 1.68 (1.06 – 2.67) 4.8 0.029 
 
ACEI, angiotensin enzyme converting inhibitor; eGFR, estimated glomerular filtration rate. 
 
 
 
 
 
 23 
 Figure 3. Proportion of patients requiring discontinuation or dose reduction of each novel oral 
anticoagulant at baseline and during follow-up, applying the EU and US product monograph 
guidance and Cockcroft-Gault equation. 
EU guidance. Percentage of patients requiring dose reduction at baseline or during follow-up. 
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Online Appendix Table 1. Baseline characteristics according to presence or absence of atrial 
fibrillation. 
 
mean (SD) or n (%) AF 
n=559 
No AF 
n=2114 
Demographics   
Age (years) 69.2 (10.3) 64.2 (11.7) 
Female sex 161 (28.8) 732 (34.6) 
Weight (kg) 86.2 (21.5) 86.1 (21.2) 
Thromboembolic risks   
Hypertension 385 (68.9) 1395 (66.0) 
Age e  75 203 (36.3) 445 (21.1) 
Diabetes Mellitus 196 (35.1) 800 (37.8) 
Stroke 92 (16.5) 189 (8.9) 
Virtual CHADS2 score   
Mean score 2.8 (1.1) 2.5 (1.0) 
1 59 (10.6) 332 (15.7) 
2 181 (32.4) 811 (38.4) 
3 211 (37.7) 717 (33.9) 
4 53 (9.5) 163 (7.7) 
5 45 (8.1) 72 (3.4) 
6 10 (1.8) 19 (0.9) 
Cardiovascular History   
Myocardial Infarction 256 (45.8) 1164 (55.1) 
Angina 295 (52.8) 1385 (65.5) 
CABG 186 (33.3) 674 (31.9) 
PCI 83 (14.8) 459 (21.7) 
Heart failure   
Ejection Fraction 39.3 (16.3) 38.3 (15.7) 
NYHA Class   
II 177 (31.7) 794 (37.6) 
III 354 (63.3) 1275 (60.3) 
IV 28 (5.0) 45 (2.1) 
Heart rate (beats/min) 71.3 (11.8) 72.0 (12.0) 
Systolic BP (mm Hg) 125.4 (18.4) 128.9 (18.7) 
Diastolic BP (mm Hg) 72.0 (10.6) 74.1 (10.7) 
Medical treatment   
ACE inhibitor 272 (48.7) 944 (44.7) 
Beta-blocker 259 (46.3) 1221 (57.8) 
Spironolactone 104 (18.6) 297 (14.0) 
Oral anticoagulation 514 (91.9) 298 (14.1) 
Digoxin 405 (72.5) 1023 (48.4) 
Amiodarone 142 (25.4) 153 (7.2) 
Diuretics 519 (92.8) 1790 (84.7) 
 
BP, blood pressure; CABG, coronary artery bypass graft surgery; NYHA, New York Heart Association; SD, standard 
deviation 
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Online Appendix Table 2. Baseline characteristics stratified by severity of renal impairment 
according to the European Medicines Agency classification using the Cockcroft-Gault estimation 
 
mean (SD) or n (%) Normal 
n=1199 
Mild 
n=918 
Moderate 
n=442 
Severe 
n=114 
Demographics     
Age (years) 58.0 (10.5) 69.2 (8.7) 73.6 (7.9) 77.3 (6.9) 
Female sex 322 (26.9) 317 (34.5) 190 (43.0) 64 (56.1) 
Weight (kg) 98.5 (20.9) 80.2 (15.1) 71.3 (14.2) 62.7 (11.7) 
Thromboembolic risks     
Hypertension 766 (63.9) 626 (68.2) 300 (67.9) 88 (77.2) 
Age e  75 65 (5.4) 276 (30.1) 228 (51.6) 79 (69.3) 
Diabetes Mellitus 470 (39.2) 315 (34.3) 172 (38.9) 39 (34.2) 
Stroke 100 (8.3) 108 (11.8) 52 (11.8) 21 (18.4) 
CHADS2 score     
Mean score 2.3 (1.0) 2.6 (1.1) 2.9 (1.0) 3.2 (1.1) 
1 247 (20.6) 117 (12.7) 24 (5.4) 3 (2.6) 
2 482 (40.2) 341 (37.1) 146 (33.0) 23 (20.2) 
3 376 (31.4) 320 (34.9) 179 (40.5) 53 (46.5) 
4 59 (4.9) 75 (8.2) 61 (13.8) 21 (18.4) 
5 32 (2.7) 52 (5.7) 25 (5.7) 8 (7.0) 
6 3 (0.3) 13 (1.4) 7 (1.6) 6 (5.3) 
Cardiovascular History     
Myocardial Infarction 573 (47.8) 516 (56.2) 266 (60.2) 65 (57.0) 
Angina 729 (60.8) 589 (64.2) 288 (65.2) 74 (64.9) 
CABG 327 (27.3) 325 (35.4) 166 (37.6) 42 (36.8) 
PCI 259 (21.6) 185 (20.2) 83 (18.8) 15 (13.2) 
Heart failure     
Ejection Fraction 39.2 (15.8) 38.3 (15.4) 37.1 (16.1) 38.8 (18.0) 
NYHA Class     
II 460 (38.4) 346 (37.7) 136 (30.8) 29 (25.4) 
III 718 (59.9) 550 (59.9) 285 (64.5) 76 (66.7) 
IV 21 (1.8) 22 (2.4) 21 (4.8) 9 (7.9) 
Heart rate (beats/min) 72.9 (12.4) 71.1 (11.6) 71.0 (11.0) 70.8 (13.1) 
Systolic BP (mm Hg) 127.7 (18.1) 128.9 (18.8) 127.3 (19.1) 130.7 (22.0) 
Diastolic BP (mm Hg) 76.1 (10.5) 72.9 (10.4) 69.8 (9.9) 69.3 (11.0) 
Medical treatment     
ACE inhibitor 568 (47.4) 419 (45.6) 190 (43.0) 39 (34.2) 
Beta-blocker 716 (59.7) 497 (54.1) 222 (50.2) 45 (39.5) 
Spironolactone 154 (12.8) 142 (15.5) 82 (18.6) 23 (20.2) 
Oral anticoagulation 438 (36.5) 346 (37.7) 191 (43.2) 57 (50.0) 
Digoxin 616 (51.4) 490 (53.4) 260 (58.8) 62 (54.4) 
Amiodarone 97 (8.1) 99 (10.8) 70 (15.8) 29 (25.4) 
Diuretics 1000 (83.4) 785 (85.5) 413 (93.4) 111 (97.4) 
 
BP, blood pressure; CABG, coronary artery bypass graft surgery; NYHA, New York Heart Association; SD, standard 
deviation 
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Online Appendix Table 3.  Sensitivity analysis excluding creatinine measurements at 6 weeks. 
Proportion of patients with stable versus worsening renal impairment across serial measurements 
stratified by atrial fibrillation, according to the European Medicines Agency classification using the 
Cockcroft-Gault, MDRD and CKD-EPI methods. 
 
 CG  MDRD  CKD-EPI  
 AF No AF AF No AF AF No AF 
n with e  2 measures 440 1738 440 1738 440 1738 
Stable renal function (%) 70.5 72.6 63.9 66.7 68.0 68.2 
Normal (> 80) (%) 26.8 35.8 18.6 28.3 22.7 32.6 
Mild (50 – 80) (%) 20.2 23.8 26.6 26.4 26.1 24.0 
Moderate (30 – 49) (%) 17.3 10.5 14.1 10.0 13.6 9.3 
Severe (15 – 30) (%) 6.1 2.4 4.5 2.1 5.5 2.3 
Stable e  moderate (%) 23.4 12.9 18.6 12.0 19.1 11.6 
Worse renal function (%) 29.5 27.4 36.1 33.3 32.0 31.8 
Mild (>50) (%) 10.9 11.9 13.6 14.7 10.7 13.8 
Moderate (30 – 49) (%) 13.9 10.6 16.4 12.8 15.2 12.3 
Severe (15 – 30) (%) 4.5 4.4 5.9 5.2 5.9 5.2 
Very Severe (< 15) (%) 0.2 0.5 0.2 0.6 0.2 0.6 
Vary e  moderate (%) 18.6 15.6 22.5 18.6 21.4 18.0 
All e  moderate (%) 42.0 28.5 41.1 30.7 40.5 29.6 
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Online Appendix Table 4.  Proportion of patients requiring discontinuation or dose reduction of 
each non-VKA oral anticoagulant at baseline and during follow-up, applying the US and EU 
product monograph guidance and Cockcroft-Gault equation. 
 
n=559 
(% relative to 
baseline) 
Baseline 
 
Additional 
6 weeks 
Additional 
14 months 
Additional 
26 months 
Cumulative 
following 
baseline 
Overall 
including 
baseline 
Europe       
Dose Reduction       
Apixaban 54 (9.7) 14 (2.5) 16 (2.9) 6 (1.1) 36 (6.4) 90 (16.1) 
Dabigatran 83 (14.8) 10 (1.8) 17 (3.0) 15 (2.7) 42 (7.5) 125 (22.4) 
Rivaroxaban 154 (27.5) 43 (7.7) 28 (5.0) 17 (3.0) 88 (15.7) 242 (43.3) 
Edoxaban 284 (50.8) 42 (7.5) 26 (4.7) 17 (3.0) 85 (15.2) 369 (66.0) 
Discontinuation       
Apixaban 0 (0) 1 (0.2) 1(0.2) 0 (0) 2 (0.4) 2 (0.4) 
Dabigatran 38 (6.8) 14 (2.5) 13 (2.3) 3 (0.5) 30 (5.4) 68 (12.2) 
Rivaroxaban 0 (0) 1 (0.2) 1(0.2) 0 (0) 2 (0.4) 2 (0.4) 
Edoxaban 0 (0) 1 (0.2) 1(0.2) 0 (0) 2 (0.4) 2 (0.4) 
US       
Dose Reduction       
Apixaban 39 (7.0) 6 (1.1) 6 (1.1) 7 (1.3) 19 (3.4) 58 (10.4) 
Dabigatran 36 (6.4) 14 (2.5) 13 (2.3) 3 (0.5) 30 (5.4) 66 (11.8) 
Rivaroxaban 154 (27.5) 43 (7.7) 28 (5.0) 17 (3.0) 88 (15.7) 242 (43.3) 
Edoxaban 154 (27.5) 43 (7.7) 28 (5.0) 17 (3.0) 88 (15.7) 242 (43.3) 
Discontinuation       
Apixaban 0 (0) 1 (0.2) 1(0.2) 0 (0) 2 (0.4) 2 (0.4) 
Dabigatran 0 (0) 1 (0.2) 1(0.2) 0 (0) 2 (0.4) 2 (0.4) 
Rivaroxaban 0 (0) 1 (0.2) 1(0.2) 0 (0) 2 (0.4) 2 (0.4) 
Edoxaban 132 (23.6) 18 (3.2) 5 (0.9) 9 (1.6) 32 (5.7) 164 (29.3) 
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